FDA’s first clearance of AI for autonomous detection of diabetic retinopathy
A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices.
Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy.
The clinical trial, which also was the first study to prospectively assess the safety of an autonomous AI system in patient care, compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults and one of the most severe complications for the 30.3 million Americans living with diabetes.
IDx-DR exceeded all pre-specified superiority endpoints in sensitivity, the ability to correctly identify a patient with disease; specificity, the ability to correctly classify a person as disease-free; and imageability, or the capability to produce quality images of the retina and determine the severity of the disease.
“The AI system’s primary role is to identify those people with diabetes who are likely to have diabetic retinopathy that requires further evaluation by an eye-care provider. The study results demonstrate the safety of autonomous AI systems to bring specialty-level diagnostics to a primary care setting, with the potential to increase access and lower cost,” says Michael Abràmoff, MD, PhD, the Robert C. Watzke Professor of Ophthalmology and Visual Sciences with UI Health Care and principal investigator on the study. He is founder and president of IDx, the company that created the IDx-DR system and funded the study.
Early detection may prevent vision loss
More than 24,000 people in the United States lose their sight to diabetic retinopathy each year. Early detection and treatment can reduce the risk of blindness by 95 percent, but less than 50 percent of patients with diabetes schedule regular exams with an eye-care specialist.
In the study, 900 adult patients with diabetes—but no history of diabetic retinopathy—were examined at 10 primary care sites across the country. Retinal images of the patients were obtained using a robotic camera, with an AI assisting the operator in getting good quality images.
Once the four images were complete, the diagnostic AI then made a clinical diagnosis in 20 seconds. The diagnostic AI detects disease just as expert clinicians do, by having detectors for the lesions characteristic for diabetic retinopathy, including microaneurysms, hemorrhages, and lipoprotein exudates.
Camera operators in the study were existing staff of the primary care clinics, and not physicians or trained photographers.
“This was much more than just a study testing an algorithm on an image. We wanted to test it in the places where it will be used, by the people who will use it, and we compared it to the highest standard in the world,” says Abràmoff, who also holds faculty appointments in the UI College of Engineering.
AI measured against gold standard
Study participants also had retinal images taken at each of the primary care clinics using specialized widefield and 3D imaging equipment without AI and operated by experienced retinal photographers certified by the Wisconsin Fundus Photograph Reading Center (FPRC)—the gold standard in grading the severity of diabetic retinopathy.
Complete diagnostic data accomplished by both the AI system and FPRC readers was available for 819 of the original 900 study participants. FPRC readers identified 198 participants with more than mild diabetic retinopathy who should be further examined by a specialist; the AI was able to correctly identify 173 of the 198 participants with disease, resulting in a sensitivity of 87 percent. Among the 621 disease-free participants identified by FPRC readers, AI identified 556 participants, for a specificity of 90 percent. The AI had a 96 percent imageability rate: of the 852 participants who had an FPRC diagnosis, 819 had an AI system diagnostic output.
The Latest on: IDx-DR
via Google News
The Latest on: IDx-DR
- How should the FDA regulate adaptive AI, software that designs itself?on October 2, 2020 at 3:16 am
One authorization was for IDx-DR, an AI-based software designed to automatically screen for diabetic retinopathy in primary care settings. The other, made by my company, Caption Health ...
- Xtrackers Harvest FTSE China A-H 50 Index UCITS ETF (DR) (AH50)on September 30, 2020 at 5:00 pm
Aim: The aim is for your investment to reflect the performance of the FTSE China A-H 50... Read full aim for Xtrackers Aim: The aim is for your investment to reflect the performance of the FTSE ...
- New Developments in FDA Regulation of AIon September 29, 2020 at 5:00 pm
For example, the documentation around FDA’s de novo decision concerning IDx-DR, 7 an artificially intelligent algorithm that analyzes eye images taken with a retinal camera to assess the possibility ...
- Diabetes Mellitus Type 2 Newson September 28, 2020 at 5:00 pm
Medscape Medical News, April 16, 2018 Alert FDA OKs AI Device to Detect Diabetic Retinopathy in Primary Care The IDx-DR device detects greater than mild diabetic retinopathy without the need for a ...
- Harnessing Machine Learning And Artificial Intelligence To Accelerate Discoveries: Updates From Bio-IT World Weston August 27, 2020 at 5:00 pm
The next series of talks looked at efforts to develop AI automated diagnostics. Ryan Amelon from IDx Technologies shared findings from a clinical trial of IDx-DR, an AI system designed to detect ...
via Bing News